News & Events
- Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
- Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
- Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
- Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
- Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
- Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
- Seres Therapeutics to Present at Three Upcoming March Conferences
- Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
- Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
- Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800
- PureTech’s Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800
- Seres Therapeutics Announces Chief Executive Officer Transition
- Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
- Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates